A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration

Trial Profile

A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs GB 102 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors GrayBug inc.
  • Most Recent Events

    • 10 Aug 2017 Status changed from planning to not yet recruiting.
    • 08 May 2017 Accoridng to GrayBug media release, this study will be initiated in Q3 2017.
    • 04 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top